Skip To Main Content
Erin Roman on Muck Rack

Erin Roman

As seen in: Bloomberg Businessweek, Bloomberg News, Yahoo Finance, BMJ Open, Yahoo, Financial Post, Newsmax, Richmond Times-Dispatch, ThinkAdvisor, Police1 and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Erin

Contact Erin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Value in psoriasis (IRIS) trial: implementing value-based healthcare in psoriasis management - a 1-year prospective clinical study to evaluate feasibility and value creation | BMJ Open

|
By Niels Hilhorst, Erin Roman, Joke Borzée, Elfie Deprez
| BMJ Open Verified
Discussion The concept of VBHC is intensively discussed nowadays as a paradigm to improve how we organise our care and allocate our resources. However, well-designed studies assessing the results of working in a value-based manner are currently scarce. Here, we have designed a trial addressing several of the core items of the VBHC agenda (measuring value, delivering care throughout an IPU, and trying to define bundled payment schemes).
Open in Who Shared Issue with article?

Thiel Backs Psychedelic-Drug Startup in Latest Funding Round

|
By Tereza Elisabeth Pusca, Erin Roman
| ndtvprofit.com
Apr 23 2020, 3:18 PMApr 23 2020, 4:18 PMApril 23 2020, 3:18 PMApril 23 2020, 4:18 PM
Open in Who Shared Issue with article?

This Tiny U.K. Drugmaker Has Soared More Than 800% in Stock Rout

|
By Joe Easton Verified, Erin Roman
| Yahoo Finance Verified
(Bloomberg) -- As the world scrambles to fight the deadly coronavirus, a microcap U.K. pharmaceutical company has seen its stock surge. Shares in Synairgen Plc have soared 845% this year, with gains accelerating in mid-March after the company got approval from U.K. regulators to start trials of its drug, SNG001, in people hospitalized with Covid-19. The company has a market capitalization of just 67 million pounds ($83 million), even after the share-price jump.
Open in Who Shared Issue with article?
See all 58 articles